Eli Lilly Threatens to Withhold 340B Discounts from Safety-Net Providers
Eli Lilly issued a June 1 ultimatum to multiple hospitals that have resisted its data submission policy, giving about 70%, or 2,350 distinct entities, compliance and around 1,000 covered entities a five-day deadline to submit claims data or lose 340B Drug Pricing Program discounts.
Objective Facts
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week. The company said that about 70%, or 2,350 distinct entities, had complied with the policy, and has sent two rounds of follow-up reminder letters to those that haven't (around 1,000 covered entities). Lilly's policy requires 340B covered entities (excluding some in states with statutory restrictions) to provide claims-level data for all pharmacy and medical dispensations, including in-house pharmacy and contract pharmacy dispenses, which will allow the company to spot instances when a drug purchase is improperly granted multiple discounts under overlapping programs. AHA President and CEO Rick Pollack described the policy as unlawful and an "extraordinary step," while Mareen Testoni, president and CEO of 340B Health, called it illegal and "a huge kick in the face to the nation's safety-net hospitals". Mareen Testoni warned that "If the federal government does not act, hundreds of other drugmakers could do the same, massively increasing costs for those hospitals that devote the most resources to caring for low-income patients," and Rick Pollack said "With [Monday's] announcement, [the Department of Health and Human Services] can no longer sit on the sidelines".
Left-Leaning Perspective
The American Hospital Association, led by President and CEO Rick Pollack, called the policy "unlawful" and said Eli Lilly will "take the extraordinary step of denying 340B discounts" in a move that "will undoubtedly harm America's most vulnerable patients and communities, forcing hospitals to divert resources away from care and towards onerous and expensive administrative burdens". Mareen Testoni, president and CEO of 340B Health, called the action "illegal" and "a huge kick in the face to the nation's safety-net hospitals". Healthcare Dive's reporting and other trade publications covering the hospital industry have emphasized the operational impossibility of the five-day deadline and the burden on safety-net providers. While acknowledging a commitment to 340B program integrity, the AHA argued that "Lilly's unilateral claims-data policy does little to address program integrity, while instead imposing enormous costs and burdens on 340B hospitals". The AHA proposed an alternative: "a neutral third-party data 'clearinghouse'" that would "identify any instances of duplicate discounts or diversion, while limiting the costs imposed on 340B hospitals and protecting their legitimate interests in maintaining data and patient privacy". Rick Pollack also disputed Lilly's claims that it made a fair effort to resolve hospitals' concerns, noting that "just two weeks ago, AHA sent a letter to Lilly offering to work together in good faith on a common solution. Lilly never responded". Clinical Trial Vanguard, writing for hospital compliance officers, noted that "for a hospital system managing hundreds of patient encounters daily, reconciling claims data across contract pharmacy chains, and operating under skeleton administrative staffing after two years of health-system budget cuts, five days is not a compliance window. It is a trap door". Hospital-aligned coverage emphasizes that Lilly's claims about data already being routinely submitted ignore the specific format, reconciliation, and rapid turnaround requirements of the ultimatum.
Right-Leaning Perspective
Eli Lilly justified the requirement as a "crucial step" to root out 340B fraud and abuse that the company takes "reluctantly". Lilly argued that collecting the data doesn't impose new burdens because it "relies on information they are already collecting and submitting to insurers," and questioned: "So why is the American Hospital Association attacking this change, falsely claiming that it is illegal and burdensome?" with the suggestion that "AHA is more committed to concealing the abuse in the 340B program because hospitals profit from it". Breitbart's analysis identified 340B-registered hospital systems that have paid tens to hundreds of millions in Medicare and Medicaid fraud settlements, arguing that "The 340B Drug Discount Program, on track to become the largest government drug program in the country, was created to help low-income patients. All too often it instead helps multibillion dollar 'non-profit' hospitals to fund ad campaigns, pad executive pay, and push out independent competitors". The article highlighted that "many of these same hospitals have been cited by the Department of Justice for Medicare and Medicaid fraud," and that "bad actors are unfortunately common. They are large, well-resourced systems that have claimed the program's benefits while defrauding the federal programs it was designed to complement". The National Consumers League, a consumer advocacy group, stated that while the 340B program "was designed to help low-income and uninsured patients access their medications through drug manufacturer discounts to hospitals... instead, sadly, 340B has veered wildly off course to the detriment of patients. Today, the program has morphed into a financial bonanza for 'non-profit' hospitals and the nation's biggest chain retail pharmacies while patients in desperate need don't get the benefits of 340B drug discounts". Right-leaning and business-focused coverage emphasizes that hospitals have lost sight of the program's original intent and that manufacturers need enforcement mechanisms.
Deep Dive
The conflict has been simmering for months, with Lilly first announcing its change-up in January and several other major drugmakers following suit shortly after. In May 2021, HRSA sent Eli Lilly a formal enforcement letter determining that Lilly's earlier contract pharmacy restrictions violated the statute, but courts declined to fully vindicate HRSA's authority, creating a legal stalemate. Lilly has not backed down—the five-day ultimatum of June 2026 is the direct operational descendant of the 2021 enforcement letter, except this time Lilly controls the clock. The 340B program itself is deeply contested. Originally, there were 1,000 covered entities in 1992; today there are more than 53,000 sites, representing more than 40 percent of the hospitals in the country. Manufacturers argue that the 340B program is not delivering on the congressional intent to expand and improve care for low-income and uninsured patients, claiming that hospitals and contract pharmacies are using revenues to maximize profits and not passing program savings on to patients. In 2024, 340B discounted sales totaled $81 billion nationwide, making it the second-largest federal drug program after Medicare Part D, with an estimated $66 billion in net revenue for participating providers—87 percent flowing to hospitals. While many covered entities use the program as Congress intended, the bad actors are unfortunately common—large, well-resourced systems that have claimed the program's benefits while defrauding federal programs it was designed to complement. Because 340B has no mechanism to distinguish between good actors and bad, the entire program pays the price. What to watch: At least six other drug companies also have announced data policies requiring 340B hospitals to provide onerous amounts of pharmacy and medical claims data in exchange for continued access to 340B pricing. Hospital groups are calling for federal intervention, saying "For months, HHS has done nothing as Lilly threatened to take these illegal actions. With today's announcement, HHS can no longer sit on the sidelines". The next critical decision point is whether HRSA or HHS will intervene before June 8, and whether courts will ultimately side with hospitals claiming the policy is unlawful or with manufacturers citing prior court rulings that allow them to request compliance data.